Work

Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases

Year: 2019

Type: review

Study designs: Systematic Review, Meta-Analysis

Source: Clinical Gastroenterology and Hepatology

DOI: 10.1016/j.cgh.2019.08.042

Authors: Nghia H. Nguyen, Jejo Koola, Parambir S. Dulai, Larry J. Prokop, William J. Sandborn, Siddharth Singh

Institutions: University of California San Diego, Mayo Clinic

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Amgen, Eli Lilly and Company, Pfizer, Gilead Sciences, Celgene, AbbVie, Shire, Takeda Pharmaceutical Company, Prometheus, Crohn's and Colitis Foundation, National Institutes of Health, Genentech, National Institute of Diabetes and Digestive and Kidney Diseases, U.S. National Library of Medicine, Janssen Biotech

Awards: Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel Diseases, G6775854128, Training Grant in Gastroenterology, G83755665, San Diego Digestive Diseases Research Center, San Diego Biomedical Informatics Education & Research (SABER)

OpenAlex ID: W2970191773

FWCI: 0.636

Cites: 36

Cited by: 40

Related to: 10